Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis.
$213.13+2.47%
报价 2026-11-06
市值
$32.23B
EV
$41.94B
PE (TTM)
49.5x
预期 PE (FY2026)
39.4x
52 周区间距高点 -27.4%
$114.44$293.69
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 5.43 → 6.16（1.1x） | 34.6 |
| FY+32028-12 | 1.2x | 5.43 → 7.10（1.3x） | 30.0 |
毛利率 67% · TTM 收入 $4539M · 基数 EPS 5.43（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ILMNIllumina, Inc. | $32.23B | +2.5% | +7.6% | 66.4% | 49.5x | 30.8x | 43.1x | |
| WATWaters Corporation | $44.93B | +1.0% | +103.6% | 58.9% | 28.0x | 18.3x | 83.3x | 高增长 |
| GMABGenmab A/S | $32.98B | +1.7% | – | 39.9% | 45.6x | 28.5x | 41.3x | |
| LHLabcorp Holdings Inc. | $29.77B | +0.9% | +5.9% | 29.8% | 27.6x | 15.9x | 23.9x | |
| DGXQuest Diagnostics Incorporated | $28.21B | +0.3% | +10.0% | 33.7% | 24.3x | 15.6x | 21.0x | GARP |
| WSTWest Pharmaceutical Services, Inc. | $27.85B | +1.9% | +11.6% | 39.7% | 45.5x | 29.2x | 62.7x | |
| THCTenet Healthcare Corporation | $22.55B | -1.1% | +4.8% | 62.5% | 8.2x | 5.6x | 6.8x | Cheap |
| ZBHZimmer Biomet Holdings, Inc. | $20.14B | -1.2% | +4.7% | 71.2% | 26.6x | 11.9x | 12.2x | |
| MEDPMedpace Holdings, Inc. | $18.27B | +2.9% | +13.5% | 31.3% | 36.9x | 28.6x | 28.4x | |
| 同行中位数 | – | – | +10.0% | 39.8% | 27.8x | 17.1x | 26.1x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-28 Q2 2026 | 2026-03-29 Q1 2026 | 2025-12-28 Q4 2025 | 2025-09-28 Q3 2025 | 2025-06-29 Q2 2025 | 2025-03-30 Q1 2025 | 2024-12-29 Q4 2024 | 2024-09-29 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.16B | $1.09B | $1.16B | $1.08B | $1.06B | $1.04B | $1.1B | $1.08B |
| Gross Margin | 66.4% | 66.1% | 67.1% | 67.6% | 67.8% | 65.8% | 65.9% | 69% |
| Operating Margin | 21.1% | 19.2% | 22.2% | 21.3% | 21% | 17.7% | 18.3% | 68.6% |
| Net Income | $207M | $134M | $334M | $150M | $235M | $131M | $187M | $705M |
| Diluted EPS | 1.35 | 0.87 | 2.17 | 0.97 | 1.5 | 0.82 | 1.17 | 4.41 |
| Operating Cash Flow | $201M | $289M | $321M | $284M | $234M | $240M | $364M | $316M |